Trial Profile
Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Monoclonal antibody 3F8 I-131 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 02 Mar 2015 Planned End Date changed from 1 Aug 2014 to 1 Aug 2016 according to ClinicalTrials.gov record.
- 02 Mar 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Aug 2016 according to ClinicalTrials.gov record.